Sanguine Biosciences
PrivateLast Round
Debt
Nov 1, 2023
Total Funding Raised
$10.22M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Sanguine Biosciences operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Debt round in November 2023.
Sanguine Biosciences is a biotechnology company that provides a platform for direct-to-patient engagement and in-home collection of annotated biospecimens for research.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sanguine Biosciences Comparables
Compare Sanguine Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CGT Global | 87% | |
| Audubon Bioscience | 85% | |
| ProteoGenex, Inc. | 85% |
For institutional investors. Book with your work email.
Sanguine Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Nov 1, 2023 | ||||
| VC Round | Jan 9, 2023 | ||||
| Grant | Feb 26, 2019 | ||||
| Seed | Mar 7, 2013 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Sanguine Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Catalio Capital Management | Debt |
| INVENT Ventures, Inc. | Seed |
| BroadOak Capital Partners | VC Round |
| National Science Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 3, 2026
Open roles increased to 207, 2.6x the trailing average.
- Jul 20, 2026
Open roles increased to 205, 12.1x the trailing average.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- has_revenueAug 10, 2026
In 2024, sanguinebio.com reaches estimated revenue of $21.1M.
For institutional investors. Book with your work email.
Sanguine Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Sanguine Biosciences's valuation, stock price, and market status.
Is Sanguine Biosciences a public or private company?
Sanguine Biosciences is a private company.
What is the current stock price of Sanguine Biosciences?
Sanguine Biosciences is a private company, so its shares have no public market price. Caplight tracks Sanguine Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Sanguine Biosciences worth (valuation)?
Valuation information for Sanguine Biosciences is not publicly available.
Can I buy Sanguine Biosciences stock?
Sanguine Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Sanguine Biosciences's last funding round?
Sanguine Biosciences's most recent funding round was Debt on November 1, 2023.
Who are the main investors in Sanguine Biosciences?
Key investors in Sanguine Biosciences include Catalio Capital Management, INVENT Ventures, Inc., BroadOak Capital Partners, National Science Foundation.
Will Sanguine Biosciences IPO soon?
No public IPO plans have been announced for Sanguine Biosciences.
How can I track Sanguine Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Sanguine Biosciences's shares on secondary markets.